Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: A literature review and modelling study

The Lancet Infectious Diseases

Volumn 15, Issue 12, 2015, Pages 1429-1437

  Teillant, Aude ^a   Gandra, Sumanth ^b   Barter, Devra ^b   Morgan, Daniel J ^b,c   Laxminarayan, Ramanan ^a,b,d  

^a PRINCETON UNIVERSITY   (United States)

^b Center for Disease Dynamics Economics and Policy   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL EFFECTIVENESS; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURGICAL INFECTION; UNITED STATES; ECONOMICS; MICROBIOLOGY; MORTALITY; NEOPLASMS; OPPORTUNISTIC INFECTIONS; STATISTICAL MODEL; SURGICAL WOUND INFECTION;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; FLUOROQUINOLONES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MODELS, STATISTICAL; NEOPLASMS; OPPORTUNISTIC INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURGICAL WOUND INFECTION;

EID: 84953336403     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00270-4     Document Type: Article

References (33)

1. Smith R, Coast J The true cost of antimicrobial resistance. BMJ 2013, 346:f1493.
2. Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013, 70:195-283.
3. Bow EJ There should be no ESKAPE for febrile neutropenic cancer patients: the dearth of effective antibacterial drugs threatens anticancer efficacy. J Antimicrob Chemother 2013, 68:492-495.
4. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014, 370:1198-1208.
5. Awad SS Adherence to surgical care improvement project measures and post-operative surgical site infections. Surg Infect 2012, 13:234-237.
6. Preventing infections in cancer patients Centers for Disease Control and Prevention, (accessed June 26, 2015). http://www.cdc.gov/cancer/preventinfections/patients.htm.
7. Number of all-listed procedures for discharges from short-stay hospitals, by procedure category and age: United States, 2010 Centers for Disease Control and Prevention, (accessed July 16, 2014). http://www.cdc.gov/nchs/data/nhds/4procedures/2010pro4_numberprocedureage.pdf.
8. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014, 64:252-271.
9. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013, 34:1-14.
10. Rangaraj G, Granwehr BP, Jiang Y, Hachem R, Raad I Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer 2010, 116:967-973.
11. Wagenlehner FME, Pilatz A, Waliszewski P, Weidner W, Johansen TEB Reducing infection rates after prostate biopsy. Nat Rev Urol 2014, 11:80-86.
12. Liss MA, Taylor SA, Batura D, et al. Fluoroquinolone resistant rectal colonization predicts risk of infectious complications after transrectal prostate biopsy. J Urol 2014, 192:1673-1678.
13. Johnson JR, Polgreen PM, Beekmann SE Transrectal prostate biopsy-associated prophylaxis and infectious complications: report of a query to the emerging infections network of the Infectious Diseases Society of America. Open Forum Infect Dis 2015, 2:ofv002.
14. Roberts MJ, Williamson DA, Hadway P, Doi SAR, Gardiner RA, Paterson DL Baseline prevalence of antimicrobial resistance and subsequent infection following prostate biopsy using empirical or altered prophylaxis: a bias-adjusted meta-analysis. Int J Antimicrob Agents 2014, 43:301-309.
15. Berríos-Torres SI, Yi SH, Bratzler DW, et al. Activity of commonly used antimicrobial prophylaxis regimens against pathogens causing coronary artery bypass graft and arthroplasty surgical site infections in the United States, 2006-2009. Infect Control Hosp Epidemiol 2014, 35:231-239.
16. Bratzler DW, Hunt DR The surgical infection prevention and surgical care improvement projects: national initiatives to improve outcomes for patients having surgery. Clin Infect Dis 2006, 43:322-330.
17. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011, 186:1830-1834.
18. Nam RK, Saskin R, Lee Y, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2013, 189:S12-S17.
19. Kirby A, Santoni N Antibiotic resistance in Enterobacteriaceae: what impact on the efficacy of antibiotic prophylaxis in colorectal surgery?. J Hosp Infect 2015, 89:259-263.
20. Vehreschild MJGT, Hamprecht A, Peterson L, et al. A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J Antimicrob Chemother 2014, 69:3387-3392.
21. Liss BJ, Vehreschild JJ, Cornely OA, et al. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection 2012, 40:613-619.
22. Arnan M, Gudiol C, Calatayud L, et al. Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 2010, 30:355-360.
23. Mihu CN, Rhomberg PR, Jones RN, Coyle E, Prince RA, Rolston KV Escherichia coli resistance to quinolones at a comprehensive cancer center. Diagn Microbiol Infect Dis 2010, 67:266-269.
24. Montassier E, Batard E, Gastinne T, Potel G, de La Cochetière MF Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis 2013, 32:841-850.
25. Bull AL, Worth LJ, Richards MJ Impact of vancomycin surgical antibiotic prophylaxis on the development of methicillin-sensitive Staphylococcus aureus surgical site infections: report from Australian Surveillance Data (VICNISS). Ann Surg 2012, 256:1089-1092.
26. Kamboj M, Chung D, Seo SK, et al. The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant 2010, 16:1576-1581.
27. Feliciano J, Teper E, Ferrandino M, et al. The incidence of fluoroquinolone resistant infections after prostate biopsy-are fluoroquinolones still effective prophylaxis?. J Urol 2008, 179:952-955.
28. Patel M, Kumar RA, Stamm AM, Hoesley CJ, Moser SA, Waites KB USA300 genotype community-associated methicillin-resistant Staphylococcus aureus as a cause of surgical site infections. J Clin Microbiol 2007, 45:3431-3433.
29. Saleh A, Khanna A, Chagin KM, Klika AK, Johnston D, Barsoum WK Glycopeptides versus β-lactams for the prevention of surgical site infections in cardiovascular and orthopedic surgery: a meta-analysis. Ann Surg 2015, 261:72-80.
30. Crawford T, Rodvold KA, Solomkin JS Vancomycin for surgical prophylaxis?. Clin Infect Dis 2012, 54:1474-1479.
31. Taylor AK, Zembower TR, Nadler RB, et al. Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. J Urol 2012, 187:1275-1279.
32. Duplessis CA, Bavaro M, Simons MP, et al. Rectal cultures before transrectal ultrasound-guided prostate biopsy reduce post-prostatic biopsy infection rates. Urology 2012, 79:556-561.
33. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003, 36:592-598.